| Zacks Company Profile for Nektar Therapeutics (NKTR : NSDQ) |
|
|
| |
| • Company Description |
| Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Pfizer, Roche, Amgen, Bristol-Myers and Eli Lilly among others. The company's most lucrative deal is with Bristol-Myers, which provided the company with significant cash resources to support progress of its pipeline and share development costs for its lead candidate, bempegaldesleukin. Nektar recognizes product sales from its manufacturing and supply agreements with several pharma companies related to products developed using its PEGylation platform. The company also earns royalty payments from the sales of products using its technology platforms. Amgen's neutropenia drug, Neulasta is one of the drugs developed using Nektar's PEGylation platform.
Number of Employees: 61 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $71.33 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,494,990 shares |
| Shares Outstanding: 20.34 (millions) |
| Market Capitalization: $1,450.97 (millions) |
| Beta: 1.34 |
| 52 Week High: $73.37 |
| 52 Week Low: $6.48 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
89.31% |
92.18% |
| 12 Week |
31.41% |
26.93% |
| Year To Date |
68.71% |
68.94% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Howard W. Robin - Chief Executive Officer and President
Robert B. Chess - Chairman of the Board
Sandra Gardiner - Interim Chief Financial Officer
Jeffrey R. Ajer - Director
Diana M. Brainard - Director
|
|
Peer Information
Nektar Therapeutics (GSAC)
Nektar Therapeutics (CASI)
Nektar Therapeutics (ALCD.)
Nektar Therapeutics (OMNN)
Nektar Therapeutics (CGPI.)
Nektar Therapeutics (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 640268306
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/11/26
|
|
Share - Related Items
Shares Outstanding: 20.34
Most Recent Split Date: 6.00 (0.07:1)
Beta: 1.34
Market Capitalization: $1,450.97 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-2.32 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-10.70 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 6.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 03/11/26 |
|
|
|
| |
